Both in Biotechnology
Lineage Cell Therapeutics vs Palisade Bio
Over the past year LCTX returned −43.4% and PALI returned +57.0%; their daily moves had a correlation of 0.14.
LCTX −43.4% PALI +57.0%Growth of $1, one year, split-adjusted
| Metric | LCTX | PALI |
|---|---|---|
| Price | $0.9557 | $1.35 |
| Market cap | $241.7M | $235.3M |
| Today | +0.87% | −6.90% |
| 1 month | −13.1% | −30.8% |
| 6 months | −39.5% | −22.9% |
| Year to date | −42.8% | −42.6% |
| 1 year | −46.6% | +46.5% |
| Revenue growth (YoY) | −61.3% | — |
| Gross margin | 100.0% | 100.0% |
| Net margin | 138.6% | −2114.8% |
| P/E (TTM) | — | — |
| Price / sales | 18.5× | 470.5× |
| Net cash | $50.8M | $125.2M |
| Dividend yield | — | — |
| Volatility (60d) | 49.1% | 72.3% |
| Short % of float | 14.7% | 17.5% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).